Skip to main content

Published locations for FDA approves topical ruxolitinib for atopic dermatitis, first JAK inhibitor for this indication in the U.S.

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA approves topical ruxolitinib for atopic dermatitis, first JAK inhibitor for this indication in the U.S.

User login

  • Reset your password
  • /content/fda-approves-topical-ruxolitinib-atopic-dermatitis-first-jak-inhibitor-indication-us
  • /clinicianreviews/article/246436/atopic-dermatitis/fda-approves-topical-ruxolitinib-atopic-dermatitis
  • /edermatologynews/article/246436/atopic-dermatitis/fda-approves-topical-ruxolitinib-atopic-dermatitis
  • /familypracticenews/article/246436/atopic-dermatitis/fda-approves-topical-ruxolitinib-atopic
  • /internalmedicinenews/article/246436/atopic-dermatitis/fda-approves-topical-ruxolitinib-atopic
  • /pediatricnews/article/246436/atopic-dermatitis/fda-approves-topical-ruxolitinib-atopic-dermatitis
  • /pediatrics/article/246436/atopic-dermatitis/fda-approves-topical-ruxolitinib-atopic-dermatitis-first
  • /internalmedicine/article/246436/atopic-dermatitis/fda-approves-topical-ruxolitinib-atopic-dermatitis
  • /dermatology/article/246436/atopic-dermatitis/fda-approves-topical-ruxolitinib-atopic-dermatitis
  • /familymedicine/article/246436/atopic-dermatitis/fda-approves-topical-ruxolitinib-atopic-dermatitis